Search

Your search keyword '"Robinson, Danielle E."' showing total 33 results
Start Over Author "Robinson, Danielle E."
33 results on '"Robinson, Danielle E."'

2. Drug utilization analysis of osteoporosis medications in seven European electronic health databases

Author

Tan, Eng Hooi, Robinson, Danielle E., Jödicke, Annika M., Mosseveld, Mees, Bødkergaard, Katrine, Reyes, Carlen, Moayyeri, Alireza, Voss, Annemarie, Marconi, Ettore, Lapi, Francesco, Reinold, Jonas, Verhamme, Katia M. C., Pedersen, Lars, Braitmaier, Malte, de Wilde, Marcel, Ruiz, Marc Far, Aragón, María, Bosco-Levy, Pauline, Lassalle, Regis, Prieto-Alhambra, Daniel, and Sanchez-Santos, Maria T.

Published
2023
Full Text
View/download PDF

5. Real‐world use and cost of health and social care services of 18,116 patients living with Alzheimer’s disease

Author

Edwards, Sophie, primary, Hahn‐Pedersen, Julie Hviid, additional, Robinson, Danielle E, additional, Chan, Mei Sum, additional, Bray, Benjamin D, additional, Clark, Alice, additional, Ivkovic, Milana, additional, Michalak, Wojciech, additional, Wichmann, Christian Ahmad, additional, Berry, Sasha D, additional, and Evans, Marc, additional

Published
2023
Full Text
View/download PDF

7. Opioid use, postoperative complications, and implant survival after unicompartmental versus total knee replacement: a population-based network study

Author

Burn, Edward, Weaver, James, Morales, Daniel, Prats-Uribe, Albert, Delmestri, Antonella, Strauss, Victoria Y, He, Ying, Robinson, Danielle E, Pinedo-Villanueva, Rafael, Kolovos, Spyros, Duarte-Salles, Talita, Sproviero, William, Yu, Dahai, Van Speybroeck, Michel, Williams, Ross, John, Luis H, Hughes, Nigel, Sena, Anthony G, Costello, Ruth, Birlie, Belay, Culliford, David, O'Leary, Caroline, Morgan, Henry, Burkard, Theresa, Prieto-Alhambra, Daniel, and Ryan, Patrick

Published
2019
Full Text
View/download PDF

12. Classification of patients with osteoarthritis through clusters of comorbidities using 633 330 individuals from Spain.

Author

Pineda-Moncusí, Marta, Dernie, Francesco, Dell'Isola, Andrea, Kamps, Anne, Runhaar, Jos, Swain, Subhashisa, Zhang, Weiya, Englund, Martin, Pitsillidou, Irene, Strauss, Victoria Y, Robinson, Danielle E, Prieto-Alhambra, Daniel, and Khalid, Sara

Subjects
OSTEOARTHRITIS diagnosis, STRUCTURAL equation modeling, NECK pain, CLASSIFICATION, PATIENTS, BACKACHE, PRIMARY health care, OSTEOARTHRITIS, SURVIVAL analysis (Biometry), METABOLIC syndrome, RESEARCH funding, COMORBIDITY, ALGORITHMS, PROPORTIONAL hazards models
Abstract

Objectives To explore clustering of comorbidities among patients with a new diagnosis of OA and estimate the 10-year mortality risk for each identified cluster. Methods This is a population-based cohort study of individuals with first incident diagnosis of OA of the hip, knee, ankle/foot, wrist/hand or 'unspecified' site between 2006 and 2020, using SIDIAP (a primary care database representative of Catalonia, Spain). At the time of OA diagnosis, conditions associated with OA in the literature that were found in ≥1% of the individuals (n  = 35) were fitted into two cluster algorithms, k -means and latent class analysis. Models were assessed using a range of internal and external evaluation procedures. Mortality risk of the obtained clusters was assessed by survival analysis using Cox proportional hazards. Results We identified 633 330 patients with a diagnosis of OA. Our proposed best solution used latent class analysis to identify four clusters: 'low-morbidity' (relatively low number of comorbidities), 'back/neck pain plus mental health', 'metabolic syndrome' and 'multimorbidity' (higher prevalence of all studied comorbidities). Compared with the 'low-morbidity' cluster, the 'multimorbidity' cluster had the highest risk of 10-year mortality (adjusted hazard ratio [HR]: 2.19 [95% CI: 2.15, 2.23]), followed by the 'metabolic syndrome' cluster (adjusted HR: 1.24 [95% CI: 1.22, 1.27]) and the 'back/neck pain plus mental health' cluster (adjusted HR: 1.12 [95% CI: 1.09, 1.15]). Conclusion Patients with a new diagnosis of OA can be clustered into groups based on their comorbidity profile, with significant differences in 10-year mortality risk. Further research is required to understand the interplay between OA and particular comorbidity groups, and the clinical significance of such results. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Risk of adverse events following the initiation of antihypertensives in older people with complex health needs:a self-controlled case series in the United Kingdom

Author

Jödicke, Annika M., Tan, Eng Hooi, Robinson, Danielle E., Delmestri, Antonella, Prieto-Alhambra, Daniel, Jödicke, Annika M., Tan, Eng Hooi, Robinson, Danielle E., Delmestri, Antonella, and Prieto-Alhambra, Daniel

Abstract

BACKGROUND: We assessed the risk of adverse events-severe acute kidney injury (AKI), falls and fractures-associated with use of antihypertensives in older patients with complex health needs (CHN). SETTING: UK primary care linked to inpatient and mortality records. METHODS: The source population comprised patients aged >65, with ≥1 year of registration and unexposed to antihypertensives in the year before study start. We identified three cohorts of patients with CHN, namely, unplanned hospitalisations, frailty (electronic frailty index deficit count ≥3) and polypharmacy (prescription of ≥10 medicines). Patients in any of these cohorts were included in the CHN cohort. We conducted self-controlled case series for each cohort and outcome (AKI, falls, fractures). Incidence rate ratios (IRRs) were estimated by dividing event rates (i) during overall antihypertensive exposed patient-time over unexposed patient-time; and (ii) in the first 30 days after treatment initiation over unexposed patient-time. RESULTS:Among 42,483 patients in the CHN cohort, 7,240, 5,164 and 450 individuals had falls, fractures or AKI, respectively. We observed an increased risk for AKI associated with exposure to antihypertensives across all cohorts (CHN: IRR 2.36 [95% CI: 1.68-3.31]). In the 30 days post-antihypertensive treatment initiation, a 35-50% increased risk for falls was found across all cohorts and increased fracture risk in the frailty cohort (IRR 1.38 [1.03-1.84]). No increased risk for falls/fractures was associated with continuation of antihypertensive treatment or overall use. CONCLUSION: Treatment with antihypertensives in older patients was associated with increased risk of AKI and transiently elevated risk of falls in the 30 days after starting antihypertensive therapy.

Published
2023

14. Classification of patients with osteoarthritis through clusters of comorbidities using 633,330 individuals from Spain

Author

Pineda-Moncusí, Marta, Dernie, Francesco, Dell'Isola, Andrea, Kamps, Anne, Runhaar, Jos, Swain, Subhashisa, Zhang, Weiya, Englund, Martin, Pitsillidou, Irene, Strauss, Victoria Y, Robinson, Danielle E, Prieto-Alhambra, Daniel, Khalid, Sara, Pineda-Moncusí, Marta, Dernie, Francesco, Dell'Isola, Andrea, Kamps, Anne, Runhaar, Jos, Swain, Subhashisa, Zhang, Weiya, Englund, Martin, Pitsillidou, Irene, Strauss, Victoria Y, Robinson, Danielle E, Prieto-Alhambra, Daniel, and Khalid, Sara

Abstract

OBJECTIVES: To explore clustering of comorbidities among patients with a new diagnosis of osteoarthritis (OA) and estimate the 10-year mortality risk for each identified cluster.METHODS: This is a population-based cohort study of individuals with first incident diagnosis of OA of the hip, knee, ankle/foot, wrist/hand, or 'unspecified' site between 2006 and 2020, using SIDIAP (a primary care database representative from Catalonia, Spain). At the time of OA diagnosis, conditions associated with OA in the literature that were found in ≥ 1% of the individuals (n = 35) were fitted into two cluster algorithms, K-means and latent class analysis (LCA). Models were assessed using a range of internal and external criteria evaluation procedures. Mortality risk of the obtained clusters was assessed by survival analysis using Cox proportional hazards.RESULTS: We identified 633 330 patients with a diagnosis of OA. Our proposed best solution used LCA to identify four clusters: 'Low-morbidity (relatively low number of comorbidities), 'Back/neck pain plus mental health', 'Metabolic syndrome' and 'Multimorbidity' (higher prevalence of all study comorbidities). Compared with the 'Low-morbidity, the 'Multimorbidity' cluster had the highest risk of 10-year mortality (adjusted HR: 2.19 [95%CI: 2.15-2.23]), followed by 'Metabolic syndrome' (adjusted HR: 1.24 [95%CI: 1.22-1.27]]) and 'Back/neck pain plus mental health' (adjusted HR: 1.12 [95%CI: 1.09-1.15]).CONCLUSION: Patients with a new diagnosis of OA can be clustered into groups based on their comorbidity profile, with significant differences in 10-year mortality risk. Further research is required to understand the interplay between OA and particular comorbidity groups, and the clinical significance of such results.

Published
2023

16. Additional file 2 of Characterising complex health needs and the use of preventive therapies in the older population: a population-based cohort analysis of UK primary care and hospital linked data

Author

Elhussein, Leena, Jödicke, Annika M., He, Ying, Delmestri, Antonella, Robinson, Danielle E., Strauss, Victoria Y., and Prieto-Alhambra, Daniel

Abstract

Additional file 2: Table S1. descriptive statistics of variables used to identify cohorts. Figure S1. Histograms of variables used to identify cohorts of complex health needs: (a) unplanned hospital admission, (b) eFI and (c) polypharmacy. Figure S2. Prevalence of Charlson morbidity index deficits/conditions - in the year prior to start - for all cohorts, overlap and background population. Table S2. a Point prevalence of the different antihypertensives classes for the Hospitalisation cohort. b: Point prevalence of the different antihypertensives classes for the frailty cohort. c: Point prevalence of the different antihypertensives classes for the polypharmacy cohort. d: Point prevalence of the different antihypertensives classes for the overlap group. e: Point prevalence of the different antihypertensives classes for the background population. Table S3. a: One-year IRs – excluding one-year prevalence of the different antihypertensives classes for the Hospitalisation cohort. b: One-year IRs – excluding one-year prevalence of the different antihypertensives classes for the frailty cohort. c: One-year IRs – excluding one-year prevalence of the different antihypertensives classes for the polypharmacy cohort. d: One-year IRs – excluding one-year prevalence of the different antihypertensives classes for the overlap group. e: One-year IRs – excluding one-year prevalence of the different antihypertensives classes for the background population.

Published
2023
Full Text
View/download PDF

19. Classification of patients with osteoarthritis through clusters of comorbidities using 633,330 individuals from Spain

Author

Pineda-Moncusí, Marta, primary, Dernie, Francesco, additional, Dell’Isola, Andrea, additional, Kamps, Anne, additional, Runhaar, Jos, additional, Swain, Subhashisa, additional, Zhang, Weiya, additional, Englund, Martin, additional, Pitsillidou, Irene, additional, Strauss, Victoria Y, additional, Robinson, Danielle E, additional, Prieto-Alhambra, Daniel, additional, and Khalid, Sara, additional

Published
2022
Full Text
View/download PDF

22. Correction to:Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B–5) chronic kidney disease: an open cohort multivariable and propensity score analysis from Funen, Denmark (Archives of Osteoporosis, (2020), 15, 1, (81), 10.1007/s11657-020-00746-z)

Author

Ali, M. Sanni, Ernst, Martin, Robinson, Danielle E., Caskey, Fergus, Arden, Nigel K., Ben-Shlomo, Yoav, Nybo, Mads, Rubin, Katrine H., Judge, Andrew, Cooper, Cyrus, Javaid, M. K., Hermann, Anne P., and Prieto-Alhambra, Daniel

Abstract

The article Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B–5) chronic kidney disease: an open cohort multivariable and propensity score analysis from Funen, Denmark, written by M. Sanni Ali & Martin Ernst & Danielle E. Robinson & Fergus Caskey & Nigel K. Arden & Yoav Ben-Shlomo & Mads Nybo & Katrine H. Rubin & Andrew Judge & Cyrus Cooper & M. K. Javaid & Anne P. Hermann & Daniel Prieto-Alhambra, was originally published Online First without Open Access. After publication in volume 15, issue 1, article number: 18 (2020) the author decided to opt for Open Choice and to make the article an Open Access publication. Therefore, the copyright of the article has been changed to

Published
2021

24. What influences patients' opinion of remission and low disease activity in psoriatic arthritis. principal component analysis of an international study of 424 patients

Author

Coates, Laura C, Robinson, Danielle E, Orbai, Ana-Maria, Kiltz, Uta, Leung, Ying-Ying, Palominos, Penelope, Cañete, Juan D, Scrivo, Rossana, Balanescu, Andra, Dernis, Emmanuelle, Meisalu, Sandra, Ruyssen-Witrand, Adeline, Eder, Lihi, de Wit, Maarten, Smolen, Josef S, Lubrano, Ennio, and Gossec, Laure

Subjects
assessment, disease activity, low disease activity, outcome measures, psoriatic arthritis, remission, spondyloarthritis, treat-to-target
Published
2021

25. Author response for 'Safety of Oral Bisphosphonates in Moderate-to-Severe Chronic Kidney Disease: A Binational Cohort Analysis'

Author

null Robinson, Danielle E., null Ali, M. Sanni, null Pallares, Natalia, null Tebe, Cristian, null Elhussein, Leena, null Abrahamsen, Bo, null Arden, Nigel K., null Ben-Shlomo, Yoav, null Caskey, Fergus J., null Cooper, Cyrus, null Dedman, Daniel, null Delmestri, Antonella, null Judge, Andrew, null Perez-Saez, Maria Jose, null Pascual, Julio, null Nogues, Xavier, null Diez-Perez, Adolfo, null Strauss, Victoria Y., null Javaid, M. Kassim, and null Prieto-Alhambra, Daniel

Published
2020

26. What influences patients’ opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study

Author

Coates, Laura C, primary, Robinson, Danielle E, additional, Orbai, Ana-Maria, additional, Kiltz, Uta, additional, Leung, Ying-Ying, additional, Palominos, Penelope, additional, Cañete, Juan D, additional, Scrivo, Rossana, additional, Balanescu, Andra, additional, Dernis, Emmanuelle, additional, Meisalu, Sandra, additional, Ruyssen-Witrand, Adeline, additional, Eder, Lihi, additional, de Wit, Maarten, additional, Smolen, Josef S, additional, Lubrano, Ennio, additional, and Gossec, Laure, additional

Published
2021
Full Text
View/download PDF

27. Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study

Author

Robinson, Danielle E, primary, Ali, M Sanni, additional, Strauss, Victoria Y, additional, Elhussein, Leena, additional, Abrahamsen, Bo, additional, Arden, Nigel K, additional, Ben-Shlomo, Yoav, additional, Caskey, Fergus, additional, Cooper, Cyrus, additional, Dedman, Daniel, additional, Delmestri, Antonella, additional, Judge, Andrew, additional, Javaid, Muhammad Kassim, additional, and Prieto-Alhambra, Daniel, additional

Published
2021
Full Text
View/download PDF

28. Estimating the population health burden of musculoskeletal conditions using primary care electronic health records

Author

Yu, Dahai, primary, Peat, George, additional, Jordan, Kelvin P, additional, Bailey, James, additional, Prieto-Alhambra, Daniel, additional, Robinson, Danielle E, additional, Strauss, Victoria Y, additional, Walker-Bone, Karen, additional, Silman, Alan, additional, Mamas, Mamas, additional, Blackburn, Steven, additional, Dent, Stephen, additional, Dunn, Kate, additional, Judge, Andrew, additional, Protheroe, Joanne, additional, and Wilkie, Ross, additional

Published
2021
Full Text
View/download PDF

29. Safety of Oral Bisphosphonates in Moderate‐to‐Severe Chronic Kidney Disease: A Binational Cohort Analysis

Author

Robinson, Danielle E, primary, Ali, M Sanni, additional, Pallares, Natalia, additional, Tebé, Cristian, additional, Elhussein, Leena, additional, Abrahamsen, Bo, additional, Arden, Nigel K, additional, Ben‐Shlomo, Yoav, additional, Caskey, Fergus J, additional, Cooper, Cyrus, additional, Dedman, Daniel, additional, Delmestri, Antonella, additional, Judge, Andrew, additional, Pérez‐Sáez, María José, additional, Pascual, Julio, additional, Nogues, Xavier, additional, Diez‐Perez, Adolfo, additional, Strauss, Victoria Y, additional, Javaid, M Kassim, additional, and Prieto‐Alhambra, Daniel, additional

Published
2021
Full Text
View/download PDF

32. Treatment of first-time traumatic anterior shoulder dislocation: the UK TASH-D cohort study

Author

Rees, Jonathan L, primary, Shah, Anjali, additional, Edwards, Katherine, additional, Sanchez-Santos, Maria T, additional, Robinson, Danielle E, additional, Delmestri, Antonella, additional, Carr, Andrew, additional, Arden, Nigel, additional, Lamb, Sarah E, additional, Rangan, Amar, additional, Judge, Andrew, additional, Pinedo-Villanueva, Rafael, additional, Holt, Tim, additional, Hopewell, Sally, additional, Prieto-Alhambra, Daniel, additional, and Collins, Gary, additional

Published
2019
Full Text
View/download PDF

33. Safety of Bisphosphonates in Moderate-to-Severe (Stage 3b-5) Chronic Kidney Disease: A Bi-National Cohort Analysis of 291,096 Patients from Spain and the United Kingdom

Author

Robinson, Danielle E., primary, Ali, M. Sanni, additional, Pallares, Natalia, additional, Tebé, Cristian, additional, Elhussein, Leena, additional, Abrahamsen, Bo, additional, Arden, Nigel K., additional, Ben-Shlomo, Yoav, additional, Caskey, Fergus, additional, Cooper, Cyrus, additional, Dedman, Daniel, additional, Delmestri, Antonella, additional, Judge, Andrew, additional, Perez-Saez, M. Jose, additional, Pascual, Julio, additional, Nogues, Xavier, additional, Diez-Perez, Adolfo, additional, Strauss, Victoria, additional, Javaid, M. Kassim, additional, and Prieto-Alhambra, Daniel, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results